Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol
(Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide
(Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability
(quality and interpretability of images).